Diagnosis and treatment of pituitary tumors

被引:28
作者
Kreutzer, J [1 ]
Fahlbusch, R [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany
关键词
acromegaly; Cushing's disease; intraoperative imaging; molecular pathogenesis; pituitary adenoma; prolactinoma; radiosurgery;
D O I
10.1097/00019052-200412000-00009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review Treatment of pituitary adenomas remains an interdisciplinary challenge involving neurosurgeons, endocrinologists and radiation oncologists. The different disciplines inaugurated advanced techniques to improve the already relatively high standard of outcome for the benefit of patients, covering molecular pathogenesis, novel therapeutic strategies for the different adenoma subtypes, developments in perioperative magnetic resonance imaging and radiosurgical management of pituitary adenomas. Recent findings Despite the progress achieved in medical treatment of hormone-secreting pituitary adenomas throughout recent years, surgery remains the primary therapy of choice except for prolactinomas. Recent studies in molecular pathogenesis aiming to find novel therapy targets and reports on new pharmacological drugs effecting GH-secreting pituitary adenomas are reviewed (for example, lanreoticle 60, SOM320 and pegvisomant). Advances in surgical treatment of pituitary macroadenomas are obtained by pre- and especially by intraoperative (high-field) IVIRI offering a higher rate of safe and complete tumor removal. Therapy pitfalls mentioned in the literature throughout the last year as well as key points in the management of pituitary adenomas with focus on acromegaly and Cushing's disease are reported. Adjuvant irradiation for recurrent or residual adenomas is often a necessity. In comparison to standard conventional radiation strategies and increasing number of radiation oncologists and neurosurgeons report their experience with radiosurgery especially for smaller tumor remnants in pituitary adenomas. Summary Recent molecular studies suggest a new level of complexity in the tumorigenisis of pituitary adenomas in terms of possible cell-type-specific molecular changes. Except for prolactinomas surgery remains the primary treatment for pituitary adenomas. New pharmacological drugs achieve very encouraging endocrine results although no long-term follow-up is available so far. The results of trans-sphenoidal surgery will further improve by modern imaging techniques, especially by applying intraoperative high-field magnetic resonance imaging and neuronavigation. The results of radiosurgical techniques with regard to tumor control are mostly convincing, but definitive conclusions on long-term recurrence and/or late complications are not reliable so far.
引用
收藏
页码:693 / 703
页数:11
相关论文
共 40 条
[31]   Transcranial echo-guided transsphenoidal surgical approach for the removal of large macroadenomas [J].
Suzuki, R ;
Asai, J ;
Nagashima, G ;
Itokawa, H ;
Chang, CW ;
Noda, M ;
Fujimoto, M ;
Fujimoto, T .
JOURNAL OF NEUROSURGERY, 2004, 100 (01) :68-72
[32]   Stereotactic radiosurgery XVI: A treatment for previously irradiated pituitary adenomas [J].
Swords, FM ;
Allan, CA ;
Plowman, PN ;
Sibtain, A ;
Evanson, J ;
Chew, SL ;
Grossman, AB ;
Besser, GM ;
Monson, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5334-5340
[33]   Early postoperative indicators of late outcome in acromegalic patients [J].
Takahashi, JA ;
Shimatsu, A ;
Nakao, K ;
Hashimoto, N .
CLINICAL ENDOCRINOLOGY, 2004, 60 (03) :366-374
[34]   Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index [J].
Tanaka, Y ;
Hongo, K ;
Tada, T ;
Sakai, K ;
Kakizawa, Y ;
Kobayashi, S .
JOURNAL OF NEUROSURGERY, 2003, 98 (02) :359-365
[35]   ACTIVATING MUTATIONS OF THE GS ALPHA-GENE IN NONFUNCTIONING PITUITARY-TUMORS [J].
TORDJMAN, K ;
STERN, N ;
OUAKNINE, G ;
YOSSIPHOV, Y ;
RAZON, N ;
NORDENSKJOLD, M ;
FRIEDMAN, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (03) :765-769
[36]   Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant [J].
Trainer, PJ ;
Drake, WM ;
Katznelson, L ;
Freda, PU ;
Herman-Bonert, V ;
van der Lely, AJ ;
Dimaraki, EV ;
Stewart, PM ;
Friend, KE ;
Vance, ML ;
Besser, GM ;
Scarlett, JA ;
Thorner, MO ;
Parkinson, C ;
Klibanski, A ;
Powell, JS ;
Barkan, AL ;
Sheppard, MC ;
Maldonado, M ;
Rose, DR ;
Clemmons, DR ;
Johannson, G ;
Bengtsson, BÅ ;
Stavrou, S ;
Kleinberg, DL ;
Cook, DM ;
Phillips, LS ;
Bidlingmaier, M ;
Strasburger, CJ ;
Hackett, S ;
Zib, K ;
Bennett, WF ;
Davis, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (16) :1171-1177
[37]   A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients [J].
van der Hoek, J ;
de Herder, WW ;
Feelders, RA ;
van der Lely, AJ ;
Uitterlinden, P ;
Boerlin, V ;
Bruns, C ;
Poon, KW ;
Lewis, I ;
Weckbecker, G ;
Krahnke, T ;
Hofland, LJ ;
Lamberts, SW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :638-645
[38]   Application of three-tesla magnetic resonance imaging for diagnosis and surgery of sellar lesions [J].
Wolfsberger, S ;
Ba-Ssalamah, A ;
Pinker, K ;
Mlynárik, V ;
Czech, T ;
Knosp, E ;
Trattnig, S .
JOURNAL OF NEUROSURGERY, 2004, 100 (02) :278-286
[39]  
Yu R, 2001, BRAIN PATHOL, V11, P328
[40]   Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas [J].
Zhang, X ;
Horwitz, GA ;
Heaney, AP ;
Nakashima, M ;
Prezant, TR ;
Bronstein, MD ;
Melmed, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :761-767